Doris K Hansen
Overview
Explore the profile of Doris K Hansen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
246
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Banerjee R, Richards A, Midha S, Afrough A, Anwer F, Atanackovic D, et al.
Blood Adv
. 2025 Mar;
PMID: 40088469
No abstract available.
2.
Hansen D, Peres L, Dima D, Richards A, Shune L, Afrough A, et al.
J Clin Oncol
. 2025 Mar;
:JCO2500453.
PMID: 40053892
No abstract available.
3.
Hansen D, Peres L, Dima D, Richards A, Shune L, Afrough A, et al.
J Clin Oncol
. 2025 Feb;
:JCO2401730.
PMID: 39965175
Purpose: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), two B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). We compare safety,...
4.
Hansen D, Bixby T, Fixler K, Shea L, Martin J, Brittle C, et al.
Support Care Cancer
. 2025 Jan;
33(2):134.
PMID: 39890679
Purpose: Stem cell transplantation (SCT) is considered standard of care for patients with newly diagnosed multiple myeloma (MM) but is still associated with substantial challenges for patients and caregivers. Given...
5.
Akhtar O, Oloyede T, Brazauskas R, Afrough A, Hashmi H, Sidana S, et al.
Blood Adv
. 2025 Jan;
PMID: 39786391
Idecabtagene vicleucel (ide-cel) is an anti-BCMA CAR-T cell therapy approved for patients with relapsed/refractory multiple myeloma (RRMM) after 2 prior lines of therapy. There is limited data on outcomes of...
6.
Gaballa M, Castaneda Puglianini O, Cohen A, Cohen A, Vogl D, Vogl D, et al.
Blood Adv
. 2024 Dec;
9(5):1171-1180.
PMID: 39729503
We investigated B-cell maturation antigen-directed chimeric antigen receptor T-cell (CAR-T) therapy in patients with relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) involvement. Ten patients received either...
7.
Freeman C, Noble J, Menges M, Villanueva R, Nakashima J, Figura N, et al.
Blood
. 2024 Dec;
PMID: 39652773
Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a breakthrough treatment for relapsed and refractory multiple myeloma (RRMM). However, these products are complex to deliver and alternative options are...
8.
Hansen D, Gautam S, Lafeuille M, Rossi C, Moore B, Tardif-Samson A, et al.
Cancer Med
. 2024 Nov;
13(21):e70308.
PMID: 39486091
Introduction: Daratumumab, lenalidomide, and dexamethasone (DRd) and bortezomib, lenalidomide, and dexamethasone (VRd) are the only preferred treatment regimens for patients with transplant-ineligible (TIE) newly diagnosed multiple myeloma (NDMM). As there...
9.
Galarza Fortuna G, Banerjee R, Savid-Frontera C, Song J, Moran-Segura C, Nguyen J, et al.
Blood Cancer J
. 2024 Oct;
14(1):180.
PMID: 39414769
We report 14 cases of immune effector cell (IEC)-associated enterocolitis following chimeric antigen receptor T-cell (CAR-T) therapy in multiple myeloma, with a 1.2% incidence overall (0.2% for idecabtagene vicleucel and...
10.
Handley G, Yepes A, Eliassen E, Dominguez G, Pasikhova Y, Klinkova O, et al.
Open Forum Infect Dis
. 2024 Oct;
11(10):ofae564.
PMID: 39411216
Background: Human herpesvirus 6B (HHV-6B) frequently reactivates following allogeneic stem cell transplant (alloHCT). Consensus guidelines note that haploidentical alloHCT may represent a high-risk population for which there is little evidence;...